Long-defined by high prices, shortages and weekly injections, weight loss drugs including Wegovy and Zepbound are expected to ...

Novo Nordisk has had a difficult year: a tumbling stock price resulting in the biggest leadership shakeup in the company's ...

Novo Nordisk is lowering prices of its top-selling obesity drug Wegovy in China, the Danish drugmaker said on Monday, as it ...

The weight loss drug market is bracing itself for a transformative year in 2026, with significant changes anticipated for GLP ...

The U.S. Food and Drug Administration's approval of an oral version of Novo Nordisk's weight-loss drug Wegovy could ...

Danish drugmaker Novo Nordisk A/S was at the forefront of the weight-loss injection boom as people discovered that its ...

Novo Nordisk has won the race to secure approval from the FDA for the first weight-loss drug to be administered orally ...

The U.S. Food and Drug Administration has approved Novo Nordisk’s Wegovy® pill, making it the first and only oral GLP-1 ...

Relief rally underway in Novo Nordisk after a difficult year for the stock which saw it lose ground to arch-competitor Eli ...

Novo Nordisk and Eli Lilly are lowering prices of their top-selling obesity drugs Wegovy and Mounjaro in China, according to ...

Novo Nordisk shares surged Tuesday after the company said it received FDA approval for an oral version of its injectable weight-loss drug Wegovy.

Novo Nordisk 's ( NVO +2.93%) shareholders must be happy to see 2025 finally come to a close. It was not a good year for the ...